Sugi Predict

Sugi Predict / Targets / ROR1

ROR1

Inactive tyrosine-protein kinase transmembrane receptor ROR1 · Q01973 · ROR1 on Sugi Atlas →

2,789 patent compounds predicted against ROR1, 2,334 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL16640183 SCHEMBL16640183 0.94 13/20
SCHEMBL15939030 SCHEMBL15939030 0.53 10/20
SCHEMBL15939408 SCHEMBL15939408 0.51 10/20
SCHEMBL12652639 SCHEMBL12652639 0.64 8/20
SCHEMBL16084945 SCHEMBL16084945 0.46 8/20
SCHEMBL16084950 SCHEMBL16084950 0.37 8/20
SCHEMBL17471729 SCHEMBL17471729 0.50 7/20
SCHEMBL17471694 SCHEMBL17471694 0.47 7/20
SCHEMBL15443267 SCHEMBL15443267 0.40 7/20
SCHEMBL15443081 SCHEMBL15443081 0.40 7/20
SCHEMBL16644588 SCHEMBL16644588 0.75 6/20
SCHEMBL16644466 SCHEMBL16644466 0.73 6/20
SCHEMBL15096062 SCHEMBL15096062 0.67 6/20
SCHEMBL589881 SCHEMBL589881 0.65 6/20
SCHEMBL16644514 SCHEMBL16644514 0.64 6/20
SCHEMBL12652759 SCHEMBL12652759 0.64 6/20
SCHEMBL16644459 SCHEMBL16644459 0.63 6/20
SCHEMBL15088585 SCHEMBL15088585 0.61 6/20
SCHEMBL17471717 SCHEMBL17471717 0.56 6/20
SCHEMBL17471695 SCHEMBL17471695 0.46 6/20

Clinical trials — most relevant to ROR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi. PHASE3COMPLETED
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer PHASE3RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Preoperative Bexarotene Treatment for Cushing's Disease PHASE1/PHASE2UNKNOWN
Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia PHASE2COMPLETED
Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. PHASE2COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) PHASE2ACTIVE_NOT_RECRUITING
Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) PHASE1/PHASE2WITHDRAWN
NCCH2006/MK010 Trial (FORTUNE Trial) PHASE2RECRUITING
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) PHASE2COMPLETED
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies PHASE1UNKNOWN
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Itacitinib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
Klotho _ LRP-6 _ Gastric Adenocarcinoma nanUNKNOWN
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
PCM1-JAK2 in Therapy Related Neoplasms nanUNKNOWN
Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment nanCOMPLETED
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment nanNOT_YET_RECRUITING
Circadian Clock Proteins in Gingival Crevicular Fluid of Individuals With and Without Circadian Rhythm Disruption nanNOT_YET_RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a ROR1 binder may also engage these)

ProteinNameSimilarity
Q9Z139 — 1.000 Q9Z139 →
Q03351 — 0.980 Q03351 →
NTRK2 BDNF/NT-3 growth factors receptor 0.977 landscape →
NTRK3 NT-3 growth factor receptor 0.977 landscape →
Q91044 — 0.974 Q91044 →
Q63604 — 0.972 Q63604 →
Q5IFJ9 — 0.972 Q5IFJ9 →
Q5IS37 — 0.972 Q5IS37 →
Q8TDF5 — 0.971 Q8TDF5 →
Q6VNS1 — 0.971 Q6VNS1 →
P24786 — 0.971 P24786 →
Q91987 — 0.971 Q91987 →
P15209 — 0.970 P15209 →
P00535 — 0.969 P00535 →
PRKD1 Serine/threonine-protein kinase D1 0.969 landscape →
Q5IS82 — 0.969 Q5IS82 →
Q8R4I7 — 0.968 Q8R4I7 →
P11273 — 0.965 P11273 →
Q01887 — 0.964 Q01887 →
Q9WTQ1 — 0.963 Q9WTQ1 →
P00534 — 0.962 P00534 →
Q62101 — 0.961 Q62101 →
P52799 — 0.960 P52799 →
Q62696 — 0.960 Q62696 →
P34925 — 0.959 P34925 →
F1LTE0 — 0.959 F1LTE0 →
Q5XIS9 — 0.959 Q5XIS9 →
Q01974 — 0.958 Q01974 →
E1C1R4 — 0.956 E1C1R4 →
P13590 — 0.956 P13590 →